Trending...
- Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand - 105
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position - 102
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
LOS ALTOS, Calif. - ncarol.com -- QView Medical, a breast cancer detection pioneer and maker of the FDA-approved artificial intelligence (AI) software system for breast cancer screening, and GE Healthcare today announced that QView's QVCAD software can be launched on GE Healthcare's Invenia™ ABUS 2.0 (Automated Breast Ultrasound), which has an open platform technology that allows the integration of third-party AI tools for the optimization of the reading workflow.
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. The powerful AI Assistant leverages intelligent algorithms to assist in detecting breast lesions, helping physicians increase their reading speed with confidence.
Following years of development, QVCAD, which was previously connected to the Invenia ABUS 2.0 through an external PC and server, is now allowing clinicians to access the software through the Invenia ABUS Viewer, streamlining clinical workflow with reducing reading time by up to 33%1, while improving clinical outcomes with experience up to 93% sensitivity for lesion detection2.
Mammography misses one third of cancers in dense breasts3, and while supplemental screening finds more cancers, it requires reasonable callback and biopsy rates4. Dense breasts increase cancer risk by 4-6 times5, affecting more than 40 percent of women3. Early cancer detection is critical to increased survival rates and improved patient care and can reduce the cost of care6.
More on ncarol.com
"ABUS combined with QVCAD provides the next crucial step in supplemental breast screening for women with dense breasts," said Bob Wang, Chairman, and CEO of QView Medical.
Brian McEathron, Vice President, General Imaging Ultrasound at GE Healthcare, said, "Our goal is to support clinicians by enabling the timely, accurate diagnosis and treatment of cancer in dense breasts. The integration of QVCAD into the ABUS reading process is a breakthrough for streamlining workflow and enhancing clinical confidence. Identifying breast cancer at the earliest possible stage has important prognostic implications: a greater number of available treatment options, increased survival rates and an improved quality of life."
QView supports the #AMIDENSE public health effort to raise awareness of breast density as a major risk factor.
About QView Medical, Inc.
QView Medical develops and sells AI image-analysis systems for the reading of 3D Automated Breast Ultrasound Systems (ABUS) The QView team has been the leader AI technologies for over twenty-five years including the development of R2 mammography CAD, R2 lung CT CAD, U-Systems ABUS and QView AI/QVCAD. QView is located in Los Altos, California. Visit our website www.qviewmedical.com for more information.
More on ncarol.com
--
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. The powerful AI Assistant leverages intelligent algorithms to assist in detecting breast lesions, helping physicians increase their reading speed with confidence.
Following years of development, QVCAD, which was previously connected to the Invenia ABUS 2.0 through an external PC and server, is now allowing clinicians to access the software through the Invenia ABUS Viewer, streamlining clinical workflow with reducing reading time by up to 33%1, while improving clinical outcomes with experience up to 93% sensitivity for lesion detection2.
Mammography misses one third of cancers in dense breasts3, and while supplemental screening finds more cancers, it requires reasonable callback and biopsy rates4. Dense breasts increase cancer risk by 4-6 times5, affecting more than 40 percent of women3. Early cancer detection is critical to increased survival rates and improved patient care and can reduce the cost of care6.
More on ncarol.com
- Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
- Holiday Magic Returns to Downtown Downers Grove November 27-29
- What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
- LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
"ABUS combined with QVCAD provides the next crucial step in supplemental breast screening for women with dense breasts," said Bob Wang, Chairman, and CEO of QView Medical.
Brian McEathron, Vice President, General Imaging Ultrasound at GE Healthcare, said, "Our goal is to support clinicians by enabling the timely, accurate diagnosis and treatment of cancer in dense breasts. The integration of QVCAD into the ABUS reading process is a breakthrough for streamlining workflow and enhancing clinical confidence. Identifying breast cancer at the earliest possible stage has important prognostic implications: a greater number of available treatment options, increased survival rates and an improved quality of life."
QView supports the #AMIDENSE public health effort to raise awareness of breast density as a major risk factor.
About QView Medical, Inc.
QView Medical develops and sells AI image-analysis systems for the reading of 3D Automated Breast Ultrasound Systems (ABUS) The QView team has been the leader AI technologies for over twenty-five years including the development of R2 mammography CAD, R2 lung CT CAD, U-Systems ABUS and QView AI/QVCAD. QView is located in Los Altos, California. Visit our website www.qviewmedical.com for more information.
More on ncarol.com
- Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
- Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
- BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
- Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
- The Seaside Art Gallery Presents
--
- Interpretation Time Using a Concurrent-Read Computer-Aided Detection System for Automated Breast Ultrasound in Breast Cancer Screening of Women With Dense Breast Tissue (Yulei Jiang). Read More: https://www.ajronline.org/doi/10.2214/AJR.18.19516
- Performance and Reading Time of Automated Breast US with or without Computer-aided Detection. Read More: https://pubs.rsna.org/doi/10.1148/radiol.2019181816
- Pisano et al. Diagnostic Performance of Digital versus Film Mammography
- Mandelson et al. Journal Natl Cancer Inst 2000; 92:1081–1087 for Breast –Cancer Screening. NEJM 2005; 353:1773
- Boyd, et al, NEJM Jan 2007
- Blumen, et al. Comparison of treatment costs for breast cancer by tumor stage and type of service
Contact
Robert M. Foley
Vice President, Marketing
QView Medical, Inc. 1-844-643-9527
info@qviewmedical.com
Robert M. Foley
Vice President, Marketing
QView Medical, Inc. 1-844-643-9527
info@qviewmedical.com
Source: QView Medical, Inc
0 Comments
Latest on ncarol.com
- Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
- Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
- Kitchen Table Economics: An Invitation to Think Differently
- Gabby Press Earns High Praise From BookLife For Book About the Dangers of Corporate AI
- Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
- CB Stuffer Announces Private Sale to Secure Future of Brand Growth
- The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
- Apex Wellness Architect Hosts Intimate Tea & Intentions Tea Bar Experience to Close Out the Year
- Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
- Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
- Lake Norman Philharmonic Annual Holiday Concert 2026
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
- ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
- Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
- Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
- The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
- Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
